KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Depreciation & Amortization (CF): 2017-2025

Historic Depreciation & Amortization (CF) for Teva Pharmaceutical Industries (TEVA) over the last 9 years, with Sep 2025 value amounting to $249.0 million.

  • Teva Pharmaceutical Industries' Depreciation & Amortization (CF) fell 3.86% to $249.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year decrease of 4.07%. This contributed to the annual value of $1.1 billion for FY2024, which is 8.15% down from last year.
  • Teva Pharmaceutical Industries' Depreciation & Amortization (CF) amounted to $249.0 million in Q3 2025, which was down 0.80% from $251.0 million recorded in Q2 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Depreciation & Amortization (CF) registered a high of $376.0 million during Q1 2021, and its lowest value of $244.0 million during Q1 2025.
  • In the last 3 years, Teva Pharmaceutical Industries' Depreciation & Amortization (CF) had a median value of $266.0 million in 2023 and averaged $268.7 million.
  • Per our database at Business Quant, Teva Pharmaceutical Industries' Depreciation & Amortization (CF) dropped by 20.16% in 2021 and then grew by 17.38% in 2022.
  • Teva Pharmaceutical Industries' Depreciation & Amortization (CF) (Quarterly) stood at $320.0 million in 2021, then declined by 4.37% to $306.0 million in 2022, then declined by 13.07% to $266.0 million in 2023, then climbed by 1.13% to $269.0 million in 2024, then dropped by 3.86% to $249.0 million in 2025.
  • Its last three reported values are $249.0 million in Q3 2025, $251.0 million for Q2 2025, and $244.0 million during Q1 2025.